SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders. Its primary drug development programs include SCI-110, targeting Tourette syndrome, Alzheimer’s disease and agitation, and obstructive sleep apnea, and SCI-110 for autism spectrum disorder and status epilepticus, conducted through its majority-owned subsidiary NeuroThera Labs Inc. The company also advances intellectual property in areas such as opioid-N-acylethanolamine combinations for pain management, neuroplastogen therapies, and the MUSE system, an endoscopic device for gastroesophageal reflux disease treatment. Additionally, SciSparc sells hemp seed oil-based nutraceutical products, including gummies, oil capsules, creams, and beauty treatments, via online marketplaces. It pursues innovative initiatives like quantum computing-enabled 3D protein modeling to enhance AI-driven drug discovery for neurological conditions. Founded in 2004 and headquartered in Tel Aviv, Israel, SciSparc operates in the pharmaceuticals and biotech sectors, emphasizing cannabinoid technologies and related IP assets.